MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00520-026-11303-8

Медицинская библиотека · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026

Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome.

Zhao Shaoli, Sun Wei, Peng Liping, Wang Chunjiang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

To explore the clinical patterns of nivolumab-induced cytokine release syndrome (CRS), and to provide a basis for diagnosis, treatment and prognosis.

METHODS

Clinical reports of nivolumab-induced CRS before March 31, 2026 were collected, and clinical data were extracted for retrospective analysis.

RESULTS

Thirty-five patients were included, with a median age of 55 years (range 3, 86). The median time for the appearance of CRS was 54.5 days (range 0.2, 391) and the median number of cycles was 3 (range 1, 17). Fever (85.7%), hypotension (57.1%), tachycardia (42.9%), fatigue (25.7%), rash (25.7%) and impaired consciousness (25.7%) were the main symptoms of patients. Laboratory tests may reveal liver injury, renal injury, elevated C-reactive protein, elevated ferritin, and elevated interleukin-6. After discontinuing nivolumab and receiving treatment with glucocorticoids and tocilizumab, 71.4% of the patients showed improvement in symptoms and clinical markers, while 28.6% of the patients died.

CONCLUSION

Nivolumab-induced CRS can lead to multi-organ functional impairment and even be fatal. During the administration of nivolumab, the possibility of CRS should be taken into consideration. Glucocorticoids and tocilizumab are widely utilized as primary therapeutic approaches for the management of CRS in clinical practice. However, given the limited available evidence and inherent clinical confounders, the standardized and optimal treatment strategy for nivolumab-induced CRS remains undefined and requires further exploration.

Для цитирования: Zhao Shaoli, Sun Wei, Peng Liping, Wang Chunjiang. Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. DOI: 10.1007/s00520-026-11303-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.